Results 251 to 260 of about 651,842 (299)
Traversing the data landscape: insights and recommendations from a case study using novel linkage of care home and health data. [PDF]
Crellin E +8 more
europepmc +1 more source
Abstract Health care is shifting towards a digital‐guided system, integrating digital diagnostics, biomarkers and therapeutics in many care pathways. However, despite rapid technological advancement and preliminary adoption accelerated by the COVID‐19 pandemic, a significant implementation gap persists. This narrative review explores the causes of this
Mees H. P. Stoop +3 more
wiley +1 more source
Introduction Introduction Reporting adverse drug reactions (ADRs) is essential for detecting drug risks. Despite legal obligations in Switzerland, underreporting remains an issue. This study assessed practice, knowledge and attitudes towards the spontaneous ADR reporting system among physicians and pharmacists.
Fiona A. Strobel +2 more
wiley +1 more source
The history of state preemption and medical device regulation: lessons for artificial intelligence oversight. [PDF]
Thomason C +3 more
europepmc +1 more source
Administrative and legal regulation of attorney-client privilege
openaire +1 more source
Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval +6 more
wiley +1 more source
Statistic tells: the regulatory pendulum of permit trajectories in China's genetic governance (2021-2024). [PDF]
Song L, Liu Z, Meng F.
europepmc +1 more source
Background Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under‐reporting remains widespread. We tested a novel method to increase reporting of ADR‐related hospitalizations.
Georgia Anita Weber +7 more
wiley +1 more source
Early and accelerated access programs for medical devices in the European Union: mapping regulatory derogations and national schemes. [PDF]
Haon B +4 more
europepmc +1 more source

